VEGFA and neoplasm: Ramucirumab (RAM), an anti‐VEGF receptor 2 (VEGFR‐2) fully human monoclonal IgG1 antibody, is a member of the antibody class of molecularly targeted therapies that works to inhibit tumor growth by preventing VEGF from binding to VEGFR‐2 and sending angiogenic signals downstream.15